Weight-loss drugs such as GLP-1 treatments (including semaglutide and tirzepatide) are becoming a major policy and financial debate in France, especially regarding who will qualify for reimbursement and how much it could cost the healthcare system.
Who would be eligible for reimbursement?
Based on current discussions and guidance from health authorities, reimbursement would likely be strictly limited to medical necessity cases, such as:
- Adults with severe obesity (typically BMI ≥ 35)
- Patients who have already failed standard weight-loss interventions (diet, lifestyle programs)
- Individuals with serious related conditions (type 2 diabetes, cardiovascular risks, hypertension)
- Prescriptions initiated only by specialists (endocrinologists or obesity clinics)
This means these treatments would not be intended for cosmetic weight loss or mild overweight cases.
Is reimbursement already in place?
- As of 2026, these medications (such as Wegovy or Mounjaro) are not yet reimbursed by the French social security system, meaning patients generally pay out of pocket.
- However, the French Health Authority (HAS) has issued positive opinions for potential reimbursement under strict conditions, meaning policy approval is progressing.
What could it cost the healthcare system?
Costs depend heavily on eligibility rules and prescription volume:
- Monthly cost per patient: roughly €180 to €440 at current market prices
- Likely reimbursement scenario: around 65% covered by social security, with the rest paid by insurance or patients
- Full coverage in specific severe cases could reach 100% (as part of long-term illness schemes)
If widely prescribed within eligible populations, total public spending could reach:
- hundreds of millions to over €1 billion per year
This is why authorities are being cautious: expanding access too broadly could significantly strain public healthcare finances.
Key takeaway
- Reimbursement is under consideration, not fully implemented yet
- Access will be strict and medically controlled
- The main challenge is balancing public health benefits with high long-term costs
- The policy debate is now focused on preventing overuse while treating severe obesity effectively
0 Comments